Chronic myloid lekemia
Conditions
Interventions
Case series:no
Sponsors
Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: (1) aged =18 years old; (2) chronic phase of CML, no prior history of accelerated or blast crisis; (3) the use of approved TKI treatment, first generation TKIs used for more than 5 years; second-generation TKIs used for more than 3 years; if first generation transformed to second-generation TKIs, taking second-generation drugs for at least 1 year; (4) molecular test results in Tongji or uion hospital: stable molecular response (MR4; = 0.01% IS) for more than 2 years for those patients who taking first generation TKIs, performed at least three months apart; Sustained MR4.0 log for more than 1 year for those patients who taking second-generation TKIs. (or domestic stable CF value of the participating units); (5) patients agree to participate in this trial and have signed an informed consent form.
Exclusion criteria
Exclusion criteria: (1) patients with suspicious blast phase; (2) patients who have previously received hematopoietic stem cell transplantation or immune cell therapy; (3) patients with severe liver and kidney dysfunction (ALT>3 UTR, AST> 3UTR, eGFR <50); (4) despite of achieving MR4.0, the routine blood was abnormal in more than two lines; (5) patients with heart disease and other tumors; (6) other researchers believe that is not suitable for clinical observation of the situation; (7) had participated in other clinical trials within 4 weeks before the start of the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| BCR-ABL1 gene; | — |
Countries
China
Contacts
Public ContactZhu Xiaojian
Tongji Medical College, Huazhong University of Science and Technology
Outcome results
None listed